Avidity Partners Management LP — 13F Holdings & Portfolio
CIK 1791827 · latest 13F-HR filed 2026-08-14
Avidity Partners Management LP manages $624.4M in 13F-reported U.S. long-equity assets across 45 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are DNTH (32.85%), CGON (15.92%), ORKA (11.59%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 10 new positions and exited 11; 19 existing positions rose in reported value and 8 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 81.9%Cumulative share of the portfolio held in the largest N positions.
DALLAS, TX 75201
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| AVIDITY PARTNERS MANAGEMENT (GP) LLC Control | GENERAL PARTNER | Less than 5% | Domestic Entity |
| GREGORY, MICHAEL, DAVID Control | MANAGING PARTNER, DIRECTOR OF RESEARCH, PRESIDENT OF BUSINESS OPERATIONS | 75% or more | Individual |
| GREGORY, MICHAEL, DAVID Control | MANAGING MEMBER | 75% or more | Individual |
| GREGORY, MICHAEL, DAVID Control | TRUSTEE | General partner | Individual |
| GREGORY AVIDITY TRUST | LIMITED PARTNER | 10–25% | Domestic Entity |
| SANTIAGO, JOSE, ANTONIO | CHIEF COMPLIANCE OFFICER | Less than 5% | Individual |
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- DIANTHUS THERAPEUTICS INC$20.4M +11.0%
- ORUKA THERAPEUTICS INC$20.3M +39.1%
- ENLIVEN THERAPEUTICS INC$11.4M +69.2%
- AKTIS ONCOLOGY INC$6.8M +77.6%
- KARYOPHARM THERAPEUTICS INC$5.2M +134.4%
Top Trims
- CONTEXT THERAPEUTICS INC-$9.0M -76.5%
- MEDTRONIC PLC-$2.6M -32.4%
- PERSPECTIVE THERAPEUTICS INC-$2.1M -9.0%
- VIR BIOTECHNOLOGY INC-$1.0M -16.4%
- PHATHOM PHARMACEUTICALS INC-$623.2K -22.3%
New Positions
- CG ONCOLOGY INC$99.4M
- MOBIA MED INC$10.7M
- IMMUNIC INC$10.3M
- SENSEONICS HLDGS INC$9.1M
- NUVECTIS PHARMA INC$3.7M
Exited Positions
- IMMUNIC INC$6.4M
- HUMANA INC$5.9M
- SCYNEXIS INC$1.9M
- ICON PLC$1.9M
- NATERA INC$1.9M
Avidity Partners Management LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $205.1M | 32.85% | 2,104,184 | SH |
| 2 | CG ONCOLOGY INC | CGON | 156944100 | $99.4M | 15.92% | 1,398,948 | SH |
| 3 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $72.4M | 11.59% | 760,424 | SH |
| 4 | JADE BIOSCIENCES INC | JBIO | 008064206 | $37.8M | 6.05% | 1,700,708 | SH |
| 5 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $27.9M | 4.47% | 550,000 | SH |
| 6 | PERSPECTIVE THERAPEUTICS INC | CATX | 46489V302 | $21.5M | 3.44% | 6,299,999 | SH |
| 7 | AKTIS ONCOLOGY INC | AKTS | 01021M104 | $15.6M | 2.50% | 484,200 | SH |
| 8 | PALVELLA THERAPEUTICS INC NE | PVLA | 697947109 | $10.7M | 1.71% | 70,000 | SH |
| 9 | MOBIA MED INC | MOBI | 60705V103 | $10.7M | 1.71% | 798,282 | SH |
| 10 | REPLIGEN CORP | RGEN | 759916109 | $10.6M | 1.70% | 77,800 | SH |
| 11 | IMMUNIC INC | IMUX | 4525EP200 | $10.3M | 1.65% | 669,941 | SH |
| 12 | SENSEONICS HLDGS INC | SENS | 81727U303 | $9.1M | 1.46% | 1,600,000 | SH |
| 13 | KARYOPHARM THERAPEUTICS INC | KPTI | 48576U205 | $9.0M | 1.45% | 924,487 | SH |
| 14 | TEVA PHARMACEUTICAL INDS LTD | TEVA | 881624209 | $6.8M | 1.09% | 200,000 | SH |
| 15 | DEXCOM INC | DXCM | 252131107 | $6.7M | 1.08% | 100,000 | SH |
| 16 | TEMPUS AI INC | TEM | 88023B103 | $6.1M | 0.97% | 105,000 | SH |
| 17 | MEDTRONIC PLC | MDT | G5960L103 | $5.5M | 0.88% | 70,000 | SH |
| 18 | VIR BIOTECHNOLOGY INC | VIR | 92764N102 | $5.3M | 0.85% | 519,300 | SH |
| 19 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $5.3M | 0.84% | 98,000 | SH |
| 20 | ENCOMPASS HEALTH CORP | EHC | 29261A100 | $4.2M | 0.68% | 42,000 | SH |
| 21 | TENAX THERAPEUTICS INC | TENX | 88032L605 | $3.9M | 0.62% | 265,934 | SH |
| 22 | NUVECTIS PHARMA INC | NVCT | 67080T108 | $3.7M | 0.59% | 200,000 | SH |
| 23 | INSULET CORP | PODD | 45784P101 | $3.7M | 0.59% | 24,000 | SH |
| 24 | BOSTON SCIENTIFIC CORP | BSX | 101137107 | $3.4M | 0.55% | 80,000 | SH |
| 25 | SATELLOS BIOSCIENCE INC | MSLE | 80401L803 | $3.0M | 0.48% | 387,769 | SH |
| 26 | ALAMAR BIOSCIENCES INC | ALMR | 010911105 | $3.0M | 0.48% | 110,000 | SH |
| 27 | CONTEXT THERAPEUTICS INC | CNTX | 21077P108 | $2.8M | 0.44% | 4,998,267 | SH |
| 28 | GILEAD SCIENCES INC | GILD | 375558103 | $2.5M | 0.40% | 20,000 | SH |
| 29 | CHARLES RIV LABS INTL INC | CRL | 159864107 | $2.3M | 0.36% | 10,000 | SH |
| 30 | PHATHOM PHARMACEUTICALS INC | PHAT | 71722W107 | $2.2M | 0.35% | 200,000 | SH |
| 31 | AVALYN PHARMACEUTICALS INC | AVLN | 05348Y105 | $2.0M | 0.32% | 60,000 | SH |
| 32 | KAILERA THERAPEUTICS INC | KLRA | 482931102 | $1.8M | 0.28% | 80,000 | SH |
| 33 | GENMAB A/S | GMAB | 372303206 | $1.4M | 0.22% | 50,000 | SH |
| 34 | INTELLIA THERAPEUTICS INC | NTLA | 45826J105 | $1.3M | 0.20% | 75,000 | SH |
| 35 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $1.2M | 0.19% | 80,000 | SH |
| 36 | ODDITY TECH LTD | ODD | M7518J104 | $1.1M | 0.17% | 70,000 | SH |
| 37 | SCYNEXIS INC | SCYX | 811292309 | $1.1M | 0.17% | 260,206 | SH |
| 38 | EVOMMUNE INC | EVMN | 30054Y107 | $996.8K | 0.16% | 75,000 | SH |
| 39 | ABBOTT LABORATORIES | ABT | 002824100 | $907.4K | 0.15% | 10,000 | SH |
| 40 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $744.8K | 0.12% | 10,000 | SH |
| 41 | PELOTON INTERACTIVE INC | PTON | 70614W100 | $591.0K | 0.09% | 100,000 | SH |
| 42 | LEGEND BIOTECH CORP | LEGN | 52490G102 | $433.2K | 0.07% | 15,000 | SH |
| 43 | BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 107924102 | $334.2K | 0.05% | 43,853 | SH |
| 44 | SAVARA INC | SVRA | 805111101 | $308.0K | 0.05% | 50,000 | SH |
| 45 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $124.2K | 0.02% | 6,660 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $624.4M | 45 | 0001791827-26-000005 |
| 2026-03-31 | 2026-05-13 | $441.9M | 46 | 0001791827-26-000003 |
| 2026-03-31 | 2026-05-28 | $493.8M | 45 | 0001791827-26-000004 |
| 2025-12-31 | 2026-02-13 | $346.7M | 39 | 0001791827-26-000002 |
| 2025-09-30 | 2025-11-14 | $439.4M | 43 | 0001791827-25-000008 |
SUITE 1220
DALLAS, TX 75201